For the latest ecancer COVID-19 resources, click on this link

Breast

Prostate & urology

Lung & pleura

Colorectal & gastro

Melanoma & skin

Head & neck

Ovary & gynaecology

+ -

Princess Margaret Hospital and University of Toronto, Canada

ESMO 33

12 - 16 Sep 2008

Published: 28 Nov 2008

Views: 14977

Rating:

Save

Prof. Ian Tannock

Blood pressure and efficacy in patients with metastatic renal cell carcinoma receiving axitinib, from ESMO 2008

Categories:
Prostate & urology

Related Videos

Developments in metastatic hormone-sensitive prostate cancer

Prof Karim Fizazi, Prof Alicia Morgans, Prof Neeraj Agarwal and Prof Laura-Maria...

Developments in metastatic hormone-sensitive prostate cancer ( Prof Karim Fizazi, Prof Alicia Morgans, Prof Neeraj Agarwal and Prof Laura-Maria Krabbe )

HCRN GU 16-257: Phase 2 trial of gemcitabine, cisplatin, plus nivolumab with sel...

Dr Matthew Galsky - Icahn School of Medicine at Mount Sinai, New York, USA

HCRN GU 16-257: Phase 2 trial of gemcitabine, cisplatin, plus nivolumab with selective bladder sparing in MIBC patients ( Dr Matthew Galsky - Icahn School of Medicine at Mount Sinai, New York, USA )

PEACE-1: Abiraterone acetate plus prednisone and/or local radiotherapy in men wi...

Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France

PEACE-1: Abiraterone acetate plus prednisone and/or local radiotherapy in men with de novo mCSPC ( Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France )

ASCO 2021: Latest on PARPi and other treatments for mCRPC

Dr Neal Shore and Prof Oliver Sartor

ASCO 2021: Latest on PARPi and other treatments for mCRPC ( Dr Neal Shore and Prof Oliver Sartor )

mCRPC: Latest developments in diagnostics and combination therapies

Dr Eleni Efstathiou, Prof Fred Saad and Prof Oliver Sartor

mCRPC: Latest developments in diagnostics and combination therapies ( Dr Eleni Efstathiou, Prof Fred Saad and Prof Oliver Sartor )

Long term outcome of enfortumab vedotin + pembrolizumab in first line locally ad...

Dr Terence Friedlander - UCSF, San Francisco, USA

Long term outcome of enfortumab vedotin + pembrolizumab in first line locally advanced or metastatic urothelial carcinoma ( Dr Terence Friedlander - UCSF, San Francisco, USA )

ASCO 2021: Renal cancer roundup

Dr Bradley McGregor - Dana-Farber Cancer Institute, Boston, USA

ASCO 2021: Renal cancer roundup ( Dr Bradley McGregor - Dana-Farber Cancer Institute, Boston, USA )

KEYNOTE-564: Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy f...

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA

KEYNOTE-564: Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )

OncoAlert and ecancer weekly roundup for April 26 - May 3, 2021

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer weekly roundup for April 26 - May 3, 2021 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

More from ecancer